Meta-level question: how do you evaluate evidence for lion mane when the human data is thin and most trials are small?
If you need three other compounds to notice the first one, you have not tested the first one.
Mechanism is not outcome, and a plausible pathway is the most expensive kind of evidence there is.
The comparison group matters more than the compound when the outcome is something as fuzzy as focus.
Most of the popular protocols are borrowed from clinical populations and applied to healthy people without comment.
Standardisation matters more than dose with botanicals, and most products say nothing about it.
Anyone got a paper worth reading on this rather than a write-up of a paper?
Read methods.
Loose evidence and no evidence are different, and people overcorrect in both directions.
Is a baseline blood test really necessary before starting something like this?
Read methods.